Telix Pharmaceuticals (NASDAQ:TLX) Given Buy Rating at HC Wainwright

Posted by Brenda Bartman on Sep 25th, 2026

Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 74.67% from the company’s current price.

Several other analysts have also issued reports on TLX. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday. Finally, Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Telix Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $20.50.

View Our Latest Analysis on Telix Pharmaceuticals

Telix Pharmaceuticals Stock Up 1.2%

Telix Pharmaceuticals stock traded up $0.14 during midday trading on Friday, reaching $11.45. The stock had a trading volume of 401,084 shares, compared to its average volume of 221,924. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $13.11. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16. The firm’s 50-day moving average price is $11.33 and its 200 day moving average price is $10.47.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the last quarter. XY Capital Ltd bought a new stake in Telix Pharmaceuticals in the 1st quarter worth approximately $120,000. Private Advisor Group LLC raised its position in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth about $1,731,000. Finally, Lazard Asset Management LLC grew its holdings in Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares during the last quarter.

Telix Pharmaceuticals Company Profile

(Get Free Report)

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.